Small fiber function in drug naïve patients with idiopathic restless legs syndrome

2012 ◽  
Vol 19 (5) ◽  
pp. 702-705 ◽  
Author(s):  
Young-Min Lim ◽  
Sung-Eun Chang ◽  
Seockhoon Chung ◽  
Bong-Hui Kang ◽  
Kwang-Kuk Kim
Keyword(s):  
Restless Legs Syndrome ◽  
Restless Legs ◽  
Small Fiber ◽  
Drug Naïve

55. Assessing the risk of restless legs syndrome in small fiber peripheral neuropathy

2017 ◽  
Vol 128 (12) ◽  
pp. e428
Author(s):  
F. Rinaldi ◽  
S. Damioli ◽  
M. Pasolini ◽  
G. De Maria ◽  
A. Padovani ◽  
...  
Keyword(s):  
Peripheral Neuropathy ◽  
Restless Legs Syndrome ◽  
Restless Legs ◽  
Small Fiber

scholarly journals 0790 The Clinical Significance of Hepcidin as a Predictive Value for Treatment Responses in Restless Legs Syndrome

SLEEP ◽  
2020 ◽  
Vol 43 (Supplement_1) ◽  
pp. A300-A301
Author(s):  
H Im
Keyword(s):  
Restless Legs Syndrome ◽  
Iron Homeostasis ◽  
Dependent Manner ◽  
Healthy Controls ◽  
Restless Legs ◽  
Inflammatory Processes ◽  
Drug Naïve ◽  
Therapeutic Responses

Abstract Introduction Restless legs syndrome (RLS) is a common sensory motor neurological disorder that is related to iron-dopamine dysregulation and immune system alteration. Hepcidin is the key regulatory hormone of systemic iron homeostasis and is related to inflammatory processes. We aimed to evaluate the clinical utility of hepcidin as a diagnostic biomarker and index of therapeutic responses in RLS patients after dopaminergic treatment. Methods Non-anemic and drug-naive RLS patients (n=18) and healthy controls (n=15) were enrolled. Hepcidin (pre-prohepcidin) and iron-related values in serum were measured upon the first visit in both groups and 12 weeks later after dopaminergic treatment in 12 RLS patients. Information about sociodemographic characteristics, sleep-related profiles, mood, and anxiety was obtained upon the first visit in all participants as well as after treatment in RLS patients. Results Hepcidin levels exhibited no significant differences between patients with drug-naïve RLS and healthy controls at a diagnosis (7.1 ± 2.4 vs. 7.0 ± 3.2 ng/ml, p = 0.978). Decreased hepcidin levels were significantly associated with decreased RLS severity (β = 0.002, 95% CI = 0.00−0.00, p = 0.005) and improved quality of life (β = 0.002, 95% CI = 0.00−7.01, p = 0.044) in a dose-dependent manner after 12 weeks of treatment with a dopamine agonist. This association was independent of age, sex, inflammatory markers, sleep quality, insomnia, daytime sleepiness, depression, and anxiety. Conclusion This study demonstrates a role of hepcidin as a predictor of therapeutic responses in RLS patients. Support This work was supported by the Korea Health technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, South Korea [grant number HI17C2072].

Restless legs syndrome in diabetic neuropathy: a frequent manifestation of small fiber neuropathy

2007 ◽  
Vol 12 (1) ◽  
pp. 50-53 ◽  
Author(s):  
Franco Gemignani ◽  
Francesca Brindani ◽  
Francesca Vitetta ◽  
Adriana Marbini ◽  
Stefano Calzetti
Keyword(s):  
Diabetic Neuropathy ◽  
Restless Legs Syndrome ◽  
Small Fiber Neuropathy ◽  
Restless Legs ◽  
Small Fiber

Restless legs syndrome in Korean patients with drug-naïve Parkinson's disease: A nation-wide study

2013 ◽  
Vol 19 (3) ◽  
pp. 355-358 ◽  
Author(s):  
Hee-Young Shin ◽  
Jinyoung Youn ◽  
Won Tae Yoon ◽  
Ji Sun Kim ◽  
Jin Whan Cho
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Restless Legs Syndrome ◽  
Korean Patients ◽  
Restless Legs ◽  
Drug Naïve

scholarly journals Functional Evaluation of Small Fiber Pathways in Primary Restless Legs Syndrome: Aδ Pathway Study

2017 ◽  
Vol 13 (12) ◽  
pp. 1455-1462 ◽  
Author(s):  
Michał Fila ◽  
Mariusz Stasiołek ◽  
Adam Markiewicz ◽  
Andrzej Bogucki
Keyword(s):  
Restless Legs Syndrome ◽  
Functional Evaluation ◽  
Restless Legs ◽  
Small Fiber

Leg Movements during Sleep in Children Treated with Serotonergic Antidepressants

SLEEP ◽  
2021 ◽  
Author(s):  
Raffaele Ferri ◽  
Maria P Mogavero ◽  
Oliviero Bruni ◽  
Daniel L Picchietti ◽  
Vidhi Kapoor ◽  
...  
Keyword(s):  
Restless Legs Syndrome ◽  
Short Interval ◽  
Time Structure ◽  
Progressive Decrease ◽  
Restless Legs ◽  
Increased Risk ◽  
Drug Naïve ◽  
Leg Movements

Abstract Study objectives To evaluate leg movements during sleep (LMS) in children taking serotonergic antidepressants, compared to those of children with restless legs syndrome (RLS) and controls, and to assess the time structure of intermovement intervals (IMI). Methods Twenty-three children (12 girls, mean age 14.1 years) on antidepressants and with a total LMS index ≥15/hour, 21 drug-naïve RLS children (11 girls, mean age 13.6 years) also with total LMS index ≥15/hour, and 35 control children (17 girls, mean age 14.3 years) were recruited. LMS were scored and a series of parameters was calculated, along with the analysis of their time structure. Results Children taking antidepressants showed higher total and periodic LMS (PLMS) indexes than both controls and RLS children, as well as higher short-interval and isolated LMS indexes than controls. LMS periodicity was highest in children on antidepressants. In children taking antidepressants, a well-defined PLMS IMI peak corresponding to ~10-60 s, with a maximum at ~20 s was present, which was much less evident in RLS patients and absent in controls. A progressive decrease of PLMS during the night and more frequent arousals were found in children on antidepressants and with RLS. Conclusions Children taking serotonergic antidepressants show higher periodicity LMS than children with RLS or controls and have a higher number of PLMS through the night. Antidepressant-associated PLMS in children seem to have features similar to PLMS of adults with RLS. Whether this is a marker of an increased risk to develop RLS later in life needs to be determined.

scholarly journals Changes in Hepcidin Serum Levels Correlate with Clinical Improvement in Idiopathic Restless Legs Syndrome Patients

2020 ◽  
Vol 9 (12) ◽  
pp. 4115
Author(s):  
Hee-Jin Im ◽  
Jee Hyun Kim ◽  
Chang-Ho Yun ◽  
Dong Wook Kim ◽  
Jeeyoung Oh
Keyword(s):  
Dopamine Agonist ◽  
Clinical Improvement ◽  
Restless Legs Syndrome ◽  
Serum Levels ◽  
Dependent Manner ◽  
Healthy Controls ◽  
Restless Legs ◽  
Serum Hepcidin ◽  
Drug Naïve

Background: Restless legs syndrome (RLS) is a common sensory motor neurological disorder that is related to iron–dopamine dysregulation and immune system alteration. We aimed to assess the effects of serum hepcidin, an iron-regulating hormone, in drug-naive RLS patients compared to healthy controls and to evaluate its role in helping to predict clinical improvement after treatment with dopamine agonist. Methods: Nonanemic and drug-naive RLS patients (n = 18) and healthy controls (n = 15) were enrolled. The serum hepcidin and iron-related values in the serum were measured upon the first visit in both groups and 12 weeks later after dopaminergic treatment in 12 patients. Information about sociodemographic characteristics, sleep-related profiles, mood and anxiety was obtained upon the first visit in all participants as well as after treatment in RLS patients. Results: Serum hepcidin levels exhibited no significant differences between patients with drug-naïve RLS and healthy controls at diagnosis (7.1 ± 2.4 vs. 7.0 ± 3.2 ng/mL, p = 0.357). Decreased hepcidin levels were significantly associated with decreased RLS severity (β = 0.002, 95% CI = 0.00−0.00, p = 0.005) and improved quality of life (β = 0.002, 95% CI = 0.00−7.01, p = 0.044) in a dose-dependent manner after 12 weeks of treatment with a dopamine agonist. This association was independent of age, sex, inflammatory markers, sleep quality, insomnia, daytime sleepiness, depression and anxiety. Conclusions: This study demonstrates the role of hepcidin in evaluating the positive therapeutic response in RLS.

Sign in / Sign up

Export Citation Format

Share Document